Lv1
86 积分 2023-07-20 加入
Tildrakizumab in Combination With Topical Halcinonide 0.1% Ointment for Treating Moderate to Severe Plaque Psoriasis
3天前
已完结
Efficacy and safety of tildrakizumab for the treatment of moderate-to-severe plaque psoriasis of the scalp: Week 52 results from a phase 3b, randomized, double-blind, placebo-controlled trial
1个月前
已完结
Efficacy, safety, and recurrence in seborrheic dermatitis: A dose-dependent analysis of oral isotretinoin (10 mg vs 20 mg)
3个月前
已完结
Isotretinoin for the management of moderate-to-severe seborrheic dermatitis: A systematic review
3个月前
已完结
Tildrakizumab in Psoriatic Patients With Current or Past Malignancy: A Real‐Life Cohort and Literature Review
3个月前
已完结
Comprehensive Post-marketing safety analysis of Tildrakizumab: insights from the FDA adverse event Reporting system
3个月前
已完结
Predicting the Time to Relapse Following Withdrawal from Different Biologics in Patients with Psoriasis who Responded to Therapy: A 12-Year Multicenter Cohort Study
3个月前
已完结
Efficacy of deucravacitinib and guselkumab in a patient with psoriasis who had experienced multiple failures of biologics: a case report
4个月前
已完结
Safety and efficacy of dual tyrosine kinase 2 inhibitor and monoclonal antibody therapy for psoriasis and psoriatic arthritis
4个月前
已完结
皖公网安备34019202002308
